Research ArticleArticle
Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis
Kavisha S. Jayasundara, Edward C. Keystone and Jayson L. Parker
The Journal of Rheumatology September 2012, jrheum.120005; DOI: https://doi.org/10.3899/jrheum.120005
Kavisha S. Jayasundara
From the Leslie Dan Faculty of Pharmacy, University of Toronto; The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; and the Department of Biology, University of Toronto, Toronto, Ontario, Canada. Dr. Parker consults for investment firms that may or may not have investments owning products in this study. He has worked in the pharmaceutical industry with infliximab. Dr. Keystone has received funding for research from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-LaRoche Inc., Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB. He has held consulting agreements and advisory board memberships with Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck, Nycomed, Pfizer Pharmaceuticals, and UCB; and he has held Speaker Honoraria agreements with Abbott Laboratories, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Inc., Merck, Pfizer Pharmaceuticals, UCB, Amgen, Abbott, and Janssen Inc. K.S. Jayasundara, M. Biotech, Leslie Dan Faculty of Pharmacy, University of Toronto; E.C. Keystone, MD, FRCPC, Director, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; J.L. Parker, PhD, Department of Biology, University of Toronto. Address correspondence to Dr. J.L. Parker, Master of Biotechnology Program, University of Toronto Mississauga, SB-2071, 3359 Mississauga Road North, Mississauga, Ontario L5L 1C6, Canada. E-mail: jayson.parker@utoronto.ca Accepted for publication July 10, 2012.
Edward C. Keystone
From the Leslie Dan Faculty of Pharmacy, University of Toronto; The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; and the Department of Biology, University of Toronto, Toronto, Ontario, Canada. Dr. Parker consults for investment firms that may or may not have investments owning products in this study. He has worked in the pharmaceutical industry with infliximab. Dr. Keystone has received funding for research from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-LaRoche Inc., Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB. He has held consulting agreements and advisory board memberships with Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck, Nycomed, Pfizer Pharmaceuticals, and UCB; and he has held Speaker Honoraria agreements with Abbott Laboratories, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Inc., Merck, Pfizer Pharmaceuticals, UCB, Amgen, Abbott, and Janssen Inc. K.S. Jayasundara, M. Biotech, Leslie Dan Faculty of Pharmacy, University of Toronto; E.C. Keystone, MD, FRCPC, Director, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; J.L. Parker, PhD, Department of Biology, University of Toronto. Address correspondence to Dr. J.L. Parker, Master of Biotechnology Program, University of Toronto Mississauga, SB-2071, 3359 Mississauga Road North, Mississauga, Ontario L5L 1C6, Canada. E-mail: jayson.parker@utoronto.ca Accepted for publication July 10, 2012.
Jayson L. Parker
From the Leslie Dan Faculty of Pharmacy, University of Toronto; The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; and the Department of Biology, University of Toronto, Toronto, Ontario, Canada. Dr. Parker consults for investment firms that may or may not have investments owning products in this study. He has worked in the pharmaceutical industry with infliximab. Dr. Keystone has received funding for research from Abbott Laboratories, Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Centocor Inc., F. Hoffmann-LaRoche Inc., Genzyme, Merck, Novartis Pharmaceuticals, Pfizer Pharmaceuticals, and UCB. He has held consulting agreements and advisory board memberships with Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Centocor Inc., F. Hoffmann-La Roche Inc., Genentech Inc., Merck, Nycomed, Pfizer Pharmaceuticals, and UCB; and he has held Speaker Honoraria agreements with Abbott Laboratories, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Inc., Merck, Pfizer Pharmaceuticals, UCB, Amgen, Abbott, and Janssen Inc. K.S. Jayasundara, M. Biotech, Leslie Dan Faculty of Pharmacy, University of Toronto; E.C. Keystone, MD, FRCPC, Director, The Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital; J.L. Parker, PhD, Department of Biology, University of Toronto. Address correspondence to Dr. J.L. Parker, Master of Biotechnology Program, University of Toronto Mississauga, SB-2071, 3359 Mississauga Road North, Mississauga, Ontario L5L 1C6, Canada. E-mail: jayson.parker@utoronto.ca Accepted for publication July 10, 2012.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Risk of Failure of a Clinical Drug Trial in Patients with Moderate to Severe Rheumatoid Arthritis
Kavisha S. Jayasundara, Edward C. Keystone, Jayson L. Parker
The Journal of Rheumatology Sep 2012, jrheum.120005; DOI: 10.3899/jrheum.120005